PDCD1 and hematologic disorder: Similarly, in addition to PD-L1, PD-1 also binds to its ligand PD-L2, which is expressed on solid tumor cells and hematological malignancies (40–45) and bears an impact on the anti-PD-1 therapy (41, 42, 46).